- Home
- ACRE vs PVLA Comparison
ACRE vs PVLA Comparison
Compare ACRE & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- PVLA
- Stock Information
- Founded
- ACRE 2011
- PVLA 2015
- Country
- ACRE United States
- PVLA United States
- Employees
- ACRE N/A
- PVLA N/A
- Industry
- ACRE Real Estate Investment Trusts
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- ACRE Real Estate
- PVLA Health Care
- Exchange
- ACRE Nasdaq
- PVLA Nasdaq
- Market Cap
- ACRE 244.2M
- PVLA 285.2M
- IPO Year
- ACRE 2012
- PVLA N/A
- Fundamental
- Price
- ACRE $4.50
- PVLA $47.30
- Analyst Decision
- ACRE Hold
- PVLA Strong Buy
- Analyst Count
- ACRE 6
- PVLA 11
- Target Price
- ACRE $5.31
- PVLA $55.36
- AVG Volume (30 Days)
- ACRE 469.5K
- PVLA 181.6K
- Earning Date
- ACRE 08-05-2025
- PVLA 08-14-2025
- Dividend Yield
- ACRE 13.33%
- PVLA N/A
- EPS Growth
- ACRE N/A
- PVLA N/A
- EPS
- ACRE N/A
- PVLA N/A
- Revenue
- ACRE $80,674,000.00
- PVLA N/A
- Revenue This Year
- ACRE N/A
- PVLA N/A
- Revenue Next Year
- ACRE N/A
- PVLA N/A
- P/E Ratio
- ACRE N/A
- PVLA N/A
- Revenue Growth
- ACRE 58.54
- PVLA N/A
- 52 Week Low
- ACRE $3.35
- PVLA $11.17
- 52 Week High
- ACRE $7.83
- PVLA $47.97
- Technical
- Relative Strength Index (RSI)
- ACRE 49.91
- PVLA N/A
- Support Level
- ACRE $4.11
- PVLA N/A
- Resistance Level
- ACRE $4.55
- PVLA N/A
- Average True Range (ATR)
- ACRE 0.17
- PVLA 0.00
- MACD
- ACRE 0.02
- PVLA 0.00
- Stochastic Oscillator
- ACRE 77.59
- PVLA 0.00
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.